Lum Erik Lawrence, Kogut Neil, Pham Thu, Danovitch Gabriel M, Bunnapradist Suphamai
Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Division of Hematology, Department of Urology David Geffen School of Medicine at UCLA, Los Angeles, CA.
Transplant Direct. 2017 Jul 21;3(8):e200. doi: 10.1097/TXD.0000000000000716. eCollection 2017 Aug.
Kidney disease is a common complication in patients with multiple myeloma. Traditionally, patients with active multiple myeloma and end-stage renal disease have been excluded from kidney transplantation due to the risk of malignancy progression. The introduction of bortezomib-based therapy for patients with multiple myeloma and renal impairment has significantly improved survival in this population. In this report, we present 2 cases of patients with active and controlled multiple myeloma who underwent successful kidney transplantation without progression of their underlying malignancy. In patients with active multiple myeloma controlled with bortezomib, kidney transplantation should be considered a valid option for patients with end-stage kidney disease.
肾脏疾病是多发性骨髓瘤患者的常见并发症。传统上，患有活动性多发性骨髓瘤和终末期肾病的患者因存在恶性肿瘤进展风险而被排除在肾移植之外。硼替佐米为主的疗法应用于患有多发性骨髓瘤和肾功能损害的患者后，显著提高了该人群的生存率。在本报告中，我们介绍了2例活动性多发性骨髓瘤得到控制的患者，他们成功接受了肾移植，且潜在恶性肿瘤未进展。对于接受硼替佐米治疗且病情得到控制的活动性多发性骨髓瘤患者，肾移植应被视为终末期肾病患者的一个有效选择。
